IN10018（Ifebemtinib）

PreclinicalSmall molecule

IInxMed (Shanghai) Co., Ltd.

IN10018（Ifebemtinib） is one of 34 small molecule programs targeting Solid Tumor. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorActive, not recruiting

Solid TumorPreclinical

Active, not recruiting

Competition

Competitive Landscape

171 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

8 2

Lenvima

Eisai

Phase 3

3 3

Lynparza

AstraZeneca

Phase 3

1 4

Bavencio

EMD Serono

Phase 3

1 5

Investigator's Choice of Chemotherapy

CCSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3

1 6

MK-4280

Merck & Co.

Phase 3

1 7

MK-4280A

Merck & Co.

Phase 3

1 8

INCB161734

Incyte

Phase 3

1 9

Yervoy

Bristol-Myers Squibb

Preclinical

1 10

Abraxane

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalActive, not recruiting

Solid Tumor

NCT06166836

Clinical

Trials by Indication[1]

Solid Tumor1 trial

A Phase 1b/II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 Combined With IN10018 in Subjects With Locally Advanced or Metastatic Solid Tumors With KRAS G12C Mutation

Active, not recruiting·IInxMed (Shanghai) Co., Ltd.·Preclinical·NCT06166836·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IN10018（Ifebemtinib）. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IN10018（Ifebemtinib） compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IN10018（Ifebemtinib）. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — InxMed (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IInxMed (Shanghai) Co., Ltd.

IN10018（Ifebemtinib）

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News